Epirubicin News and Research

RSS

Cell-based method can predict how breast cancer patients will respond to treatments

Researchers at Karolinska Institutet in Sweden have developed a method that should be able to predict whether a patient with breast cancer will benefit from a particular treatment or not.

27 Dec 2022

New advice aims to reduce the cardiac side effects of cancer treatment

The first European Society of Cardiology Guideline on cardio-oncology is published online today in European Heart Journal.

26 Aug 2022

Novel approach to molecular drug design paves way for promising bladder cancer therapy

A new approach to molecular drug design has yielded a highly promising bladder cancer drug, which induced rapid shedding of tumor cells and resulted in a significant reduction in tumour size when used in clinical trials.

28 Jun 2021

Nanomedicine-based strategy enhances anti-PD1 therapy to eradicate PTEN-negative GBM

A nanomedicine-based strategy for chemo-immunotherapy (CIT) of glioblastoma (GBM), which has the worst prognosis among brain tumors, was successfully developed.

7 Aug 2020

Nab-Paclitaxel drug combo reduces risk of breast cancer recurrence

A recent large German study has shown that a new combination therapy for breast cancer treatment leads to a lowered risk of the disease coming back. A commentary on this landmark clinical trial has been published in the latest issue of the Journal of Clinical Oncology by the researchers Masey Ross and Charles Geyer Jr. from the VCU Massey Cancer Center. The commentary was titled, “Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer?”

27 Aug 2019

European Commission approves Pfizer’s first oncology biosimilar

Pfizer Inc. today announced the European Commission has approved TRAZIMERA, a biosimilar to Herceptin (trastuzumab), for the treatment of human epidermal growth factor overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

31 Jul 2018

Japanese researchers find new way for increasing effectiveness of drug delivery to brain tumors

For a cancer drug to be successful, it needs to reach the malignant tumor site. Researchers in Japan have now found a way for increasing the effectiveness of drug delivery to certain types of brain tumors, by packing epirubicin, a known antitumor agent, in specially designed polymeric micelles.

13 Sep 2017

New trial confirms superiority of triplet regimen over standard care in resectable esophago-gastric cancer

The superiority of docetaxel based triplet therapy over standard care in patients with resectable oesophago-gastric cancer has been confirmed in late-breaking results from the FLOT4 trial presented at the ESMO 2017 Congress in Madrid.

8 Sep 2017

Chemotherapy drug effective at preventing breast cancer's return, gives patients a better quality of life

The chemotherapy drug capecitabine gives patients a better quality of life and is as effective at preventing breast cancer from returning as the alternative regimen called CMF, when given following epirubicin.

7 Jun 2017

Chemoradiotherapy and post-operative chemotherapy provide similar outcomes in gastric cancer patients

Post-operative treatment intensification with chemoradiotherapy does not achieve better outcomes when compared to post-operative chemotherapy in patients with gastric cancer who have already undergone pre-operative chemotherapy, according to phase III data presented at the ESMO 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain.

4 Jul 2016

DECT trial shows combination of epirubicin and trastuzumab improves outcomes in breast cancer patients

The study entitled "A phase II neoadjuvant sequential regimen of docetaxel followed by high-dose epirubicin in combination with cyclophosphamide administered concurrently with trastuzumab.

23 May 2016

Multi-gene test can help identify early breast cancer patients who can safely be spared chemotherapy

Researchers have shown for the first time that it is possible to use a multi-gene test to identify patients with early breast cancer who can be spared chemotherapy and who will still be alive and well five years after diagnosis.

11 Mar 2016

Attaching Epirubicin drug to nanodiamonds eliminates chemoresistant cancer stem cells

A study led by the National University of Singapore found that attaching chemotherapy drug Epirubicin to nanodiamonds effectively eliminates chemoresistant cancer stem cells. The findings were first published online in ACS Nano, the official journal of the American Chemical Society, in December 2014.

26 Jan 2015

Tumor-infiltrating lymphocytes may be good biomarker of response to trastuzumab in breast cancer

Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

12 Dec 2013

New drug combination therapy effective for patients with HER2-positive breast cancer

Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes, according to results from the BETH study presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

11 Dec 2013

Epirubicin News and Research

Cell-based method can predict how breast cancer patients will respond to treatments

New advice aims to reduce the cardiac side effects of cancer treatment

Novel approach to molecular drug design paves way for promising bladder cancer therapy

Nanomedicine-based strategy enhances anti-PD1 therapy to eradicate PTEN-negative GBM

Nab-Paclitaxel drug combo reduces risk of breast cancer recurrence

European Commission approves Pfizer’s first oncology biosimilar

Japanese researchers find new way for increasing effectiveness of drug delivery to brain tumors

New trial confirms superiority of triplet regimen over standard care in resectable esophago-gastric cancer

Chemotherapy drug effective at preventing breast cancer's return, gives patients a better quality of life

Chemoradiotherapy and post-operative chemotherapy provide similar outcomes in gastric cancer patients

DECT trial shows combination of epirubicin and trastuzumab improves outcomes in breast cancer patients

Multi-gene test can help identify early breast cancer patients who can safely be spared chemotherapy

Attaching Epirubicin drug to nanodiamonds eliminates chemoresistant cancer stem cells

Tumor-infiltrating lymphocytes may be good biomarker of response to trastuzumab in breast cancer

New drug combination therapy effective for patients with HER2-positive breast cancer

Researchers develop nanodiamond delivery system for triple-negative breast cancer

Clinigen announces acquisition of Cardioxane from Novartis

Precision Therapeutics’ ChemoFx test feasible in cervical cancer

Study identifies potential biomarkers associated with chemo resistant breast cancers

GeparQuinto study data on bevacizumab plus chemotherapy in early breast cancer to be presented at 33rd CTRC-AACR

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News